Loading
Guardant Health, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 30 Jun 2026.
Guardant Health, Inc.: what insiders have been doing
Guardant Health, Inc., founded in 2012, is a Healthcare & Pharma company based in Redwood City, United States. Its directors and officers file their transactions with SEC (Form 4). 30 insiders have disclosed 269 filings since 18 October 2025.
Purchases and sales both appear in the filings: 1 purchase (1 insider) and 59 sales (14 insiders, €48.0M). The amount is not disclosed for 11 filings. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The largest single trade was a sale of €7.4M by Eltoukhy Helmy, published on 17 December 2025. The buyers include 1 senior executive.
The most recent open-market purchase was published on 30 June 2026, 109 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Compared with its exchange (5,813 companies, median 19 filings), a count of 269 filings is above the norm. Since 2021, the database holds 7 purchases and 89 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 982.0 m USD and net income of -416.3 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
650
Thresholds
n/a
Buy Volume
€9M
7 ops. · all time
Sell Volume
€65M
89 ops. · all time
Who traded when
BuySaleTariq Musa19 sales
AmirAli Talasaz11 sales
Helmy Eltoukhy9 sales
Kumud Kalia1 buy7 sales
Terilyn J. Monroe8 sales
Chris Freeman5 sales
+9 other insiders
Since the insiders bought
- -7.2%Entry US$170.77 · Close 16 Oct 2026 US$158.46
- -37.5%Entry US$27.94 · Close at T+365 US$17.45
- -37.2%Entry US$28.26 · Close at T+365 US$17.74
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Guardant Health, Inc. Strong Buy (bullish), based on 25 analysts. Average price target: US$201.64.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 17,635 of 24,148 companies
36.2
score / 100
Value29
Quality43
FCF yld-1.1%
Earn yld-2.0%
EV/EBITDA·
ROE·
Gross mgn64%
Net mgn-42%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$158.60
Analyst consensus
25 analystsStrong buy
US$105.00Target US$201.64(+27%)US$240.00
Income statement
RevenueUS$982M
Gross profitUS$633M64% margin
EBITDA-US$373.9M-38% margin
Net income-US$416.3M-38.3% margin
Valuation
PER (forward)-388.1x
Beta1.58
Balance sheet & cash
Market capUS$21.3B
Total debtUS$1.7B
Free Cash Flow-US$233.1M
Profitability & ownership
ROA-18.1%
% insiders4.0%
% institutions101.0%
Last declaration on 16 October 2026
Declarations650 total
116 shares@ US$165.8793CommonSEC144:0001921094-26-001095
69 shares@ US$159.890.0001% mcap6.8% of flowCommon StockSEC:0001402256-26-000010:0
69 shares@ US$159.88410.0001% mcap7.3% of flowCommonSEC144:0001921094-26-001089
137 shares0Common StockSEC:0001402256-26-000008:0
1,496 shares0Common StockSEC:0001737840-26-000022:3
2,659 shares0Common StockSEC:0001652956-26-000020:0
1,607 shares0Common StockSEC:0001927831-26-000024:0
1,084 shares0Common StockSEC:0001927831-26-000024:1
1,929 shares0Common StockSEC:0001871615-26-000018:0
3,143 shares@ US$174.752.0% of flowCommon StockSEC:0001871615-26-000018:4
1,340 shares0Common StockSEC:0001977179-26-000018:0
1,668 shares0Common StockSEC:0001977179-26-000018:1
2,817 shares0Common StockSEC:0001753159-26-000022:0
23,997 shares0Common StockSEC:0001753159-26-000022:2
2,817 shares0Common StockSEC:0001752968-26-000018:0
23,997 shares0Common StockSEC:0001752968-26-000018:2
9,716 shares0Common StockSEC:0001752968-26-000018:3
2,527 shares0Common StockSEC:0001871615-26-000018:2
3,324 shares0Common StockSEC:0001977179-26-000018:2
1,701 shares0Common StockSEC:0001977179-26-000018:3
974 shares0Common StockSEC:0001737840-26-000022:0
1,668 shares0Common StockSEC:0001737840-26-000022:1
2,925 shares0Common StockSEC:0001737840-26-000022:2
3,706 shares@ US$174.7517.2% of flowCommon StockSEC:0001737840-26-000022:4
1,360 shares0Common StockSEC:0001652956-26-000020:1
25 of 650 declarations
About Guardant Health, Inc.
Guardant Health, Inc. is a U.S.-based precision oncology and liquid biopsy company listed on the NASDAQ under ticker GH. Headquartered in Palo Alto, California, in the United States, the company was founded in 2012 and has built a differentiated platform focused on using blood-based testing, tissue testing, clinical datasets, and AI analytics to help clinicians detect, characterize, and monitor cancer more effectively. It has become one of the best-known names in molecular diagnostics for oncology. ([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Surpasses-500-Peer-Reviewed-Publications-Milestone/default.aspx?utm_source=openai))
Guardant’s business model is organized around three main pillars. The Oncology segment includes liquid and tissue-based genomic testing for patients with advanced and early-stage cancers. The Screening segment is centered on cancer screening, most notably Shield, the company’s blood test for colorectal cancer screening. The Biopharma & Data business monetizes real-world clinical-genomic data and related services for pharmaceutical partners, supporting drug development and the creation of companion diagnostics. Key products in the portfolio include Guardant360 Liquid, Guardant360 CDx, Guardant360 Tissue, Guardant Reveal, and Shield. ([about.guardanthealth.com](https://about.guardanthealth.com/products/tests-for-patients-with-early-and-advanced-stage-cancer/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Guardant Health is among the global leaders in liquid biopsy. Its edge comes from the scale and depth of its data assets, its scientific publication record, clinical adoption across major cancer centers, and its ability to move assays into FDA-cleared companion diagnostic roles and reimbursement pathways. The company stated in 2024 that it had surpassed 500 peer-reviewed publications featuring its technology, underscoring its scientific credibility in a highly competitive field. ([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2024/Guardant-Health-Surpasses-500-Peer-Reviewed-Publications-Milestone/default.aspx?utm_source=openai))
Recent milestones have been material. In January 2026, Guardant received additional FDA approvals for Guardant360 CDx, including in BRAF V600E-mutant metastatic colorectal cancer, and on May 4, 2026, in ESR1-mutated ER+/HER2- advanced breast cancer. In March 2026, Shield became more widely accessible through Quest Diagnostics’ national ordering and collection network. Guardant also announced a multi-year strategic collaboration with Merck in January 2026, reinforcing the company’s companion-diagnostics and smart-platform strategy. In its 2026 outlook, the company guided to full-year revenue of $1.25 billion to $1.28 billion. ([investors.guardanthealth.com](https://investors.guardanthealth.com/press-releases/press-releases/2026/Guardant-Health-Receives-FDA-Approval-for-Guardant360-CDx-as-Companion-Diagnostic-for-BRAFTOVI-encorafenib-Combination-in-Patients-with-BRAF-V600E-Mutant-Metastatic-Colorectal-Cancer/default.aspx?utm_source=openai))
For investors in France, Belgium, and Switzerland, Guardant Health remains a growth-oriented healthcare name with strong strategic positioning, but it is still dependent on commercial execution, reimbursement expansion, and broader clinical adoption of blood-based cancer diagnostics on the NASDAQ market in the United States.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
